Halozyme Therapeutics HALO Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssets.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's other non-current assets?
- Halozyme Therapeutics (HALO) reported other non-current assets of $15.29M in Q1 2026.
- How has Halozyme Therapeutics's other non-current assets changed year-over-year?
- Halozyme Therapeutics's other non-current assets increased by 3.8% year-over-year, from $14.73M to $15.29M.
- What is the long-term trend for Halozyme Therapeutics's other non-current assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's other non-current assets has grown at a 18.0% compound annual growth rate (CAGR), from $4.78M to $10.93M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.